Biorce ESP SL
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- $56M
Investors
- 8
About Biorce ESP SL
Biorce, based in Spain, is a provider of advanced clinical AI solutions aimed at enhancing drug development processes for pharmaceutical companies and research organizations. Founded in 2024, by Pedro Coelho, Biorce operates from Barcelona, Spain, focusing on innovative clinical solutions. Biorce's primary offering is its Clinical AI Assistant, known as Jarvis, designed to enhance drug development processes through artificial intelligence. Jarvis facilitates smart study design, protocol development, feasibility analysis, and targeted patient recruitment, thereby streamlining the clinical trial process for pharmaceutical companies and research organizations. This innovative tool empowers patients by helping them identify available clinical trials, thereby reducing the burden of finding relevant studies that suit their medical needs. Biorce primarily targets the pharmaceutical and healthcare sectors, aiming to improve patient engagement and optimize trial efficiency. Biorce’s revenue model primarily revolves around subscriptions for its Clinical AI Assistant, Jarvis, which is offered to pharmaceutical companies and clinical research organizations. Clients engage in annual contracts that provide continuous access to the platform, enabling them to leverage its capabilities for multiple clinical trials throughout the subscription period. Additionally, Biorce may establish partnerships with research institutions, further enhancing its service offerings and generating collaborative revenue streams. Specific pricing plans for the Jarvis platform are customized based on client needs and the scale of implementation, allowing for flexibility in transaction structures. By delivering a robust AI solution, Biorce aims to strengthen its position in the biopharmaceutical industry while facilitating more efficient drug development processes for its clients. Specific expansion strategies include introducing new features for Jarvis and targeting additional geographic regions, although the details on release dates and specific regions are yet to be disclosed.
Who invested in Biorce ESP SL
8 investors across 2 rounds
See all investors in Biorce ESP SL
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biorce ESP SL
Who invested in Biorce ESP SL?
Biorce ESP SL has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biorce ESP SL raised?
Biorce ESP SL has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Biorce ESP SL last raise money?
Biorce ESP SL's most recent round on record is a Series A, in Jan 2026.
What does Biorce ESP SL do?
Biorce, based in Spain, is a provider of advanced clinical AI solutions aimed at enhancing drug development processes for pharmaceutical companies and research organizations.
Where is Biorce ESP SL headquartered?
Biorce ESP SL is headquartered in Spain.
Which VCs invest in companies like Biorce ESP SL?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Biorce ESP SL's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Biorce ESP SL? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.